References
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24
- Figlin, RA, Hutson, TE, Tomczak, P, , et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Oral (abstract 5024). Presented at the 44th American Society of Clinical Oncology Annual meeting, Chicago, USA, May, 30–June3, 2008.
- Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomized controlled trial. Lancet 2006; 368: 1329–38
- Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204–12
- Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332–44
- Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370(9604)2011–19
- Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474–81
- Pfizer Inc . SUTENT, Summary of Product Characteristics. January, 2008. Accessed 23/04/2008. http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp&documentid=18531.
- Porta, C, Szczylik, C, Bracarda, S, , et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). Oral (abstract 5114). Presented at the 44th American Society of Clinical Oncology Annual meeting, Chicago, USA, May, 30–June3, 2008.
- Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remiack SC. Drug insight: Vascular disrupting agents and angiogenesis–novel approaches for drug delivery. Nat Clin Pract Oncol 2006; 3: 682–92
- Joensuu H. Cardiotoxicity of sunitinib. Lancet 2007; 370: 1978–9